Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Clinical and Experimental Immunology|March 5, 1998
Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. The AIDS Vaccine Evaluation GroupT G Evans, T Fitzgerald, D C Gibbons, et al.
The Journal of Infectious Diseases|March 11, 1991
Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipientsM C Keefer, W Bonnez, N J Roberts, et al.
The Journal of Infectious Diseases|August 1, 1993
Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccinesN el-Daher, M C Keefer, R C Reichman, et al.
Antimicrobial Agents and Chemotherapy|May 11, 1991
Single-dose trospectomycin for chlamydial urethritis in menM C Keefer, M A Menegus, M A Nasello, et al.
Antiviral Research|February 1, 1989
Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza AP D Reuman, D I Bernstein, M C Keefer, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 22, 1998
Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trialA R Sheon, L Wagner, M J McElrath, et al.
Annals of Internal Medicine|October 15, 1994
Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials GroupR B Belshe, M L Clements, M C Keefer, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|December 20, 2022
Exploring a community's understanding of HIV vaccine‑induced seropositivity in a South African research settingM Malahleha, A Dilraj, J Jean, et al.
The Journal of Infectious Diseases|February 1, 1997
Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupW B Paxton, R W Coombs, M J McElrath, et al.
Vaccine|June 12, 2003
Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trialsP B Gilbert, Y-L Chiu, M Allen, et al.
Pageof 3